Table 7.

Breakdown costs by health state and total costs, over 5 years (€)

	Stable initiation	Stable prevention	Stable non-treated	Relapse hospitalisation	Relapse non-hospitalisation	AEs	Total costs undiscounted	Total costs discounteda
OO	1248	10,848	228	39,450	707	2630	55,113	50,379
PLAI	5112	14,387	239	33,365	639	1628	55,370	50,880
RLAI	8496	14,811	239	33,705	626	1627	59,504	54,952
HLAI	4635	10,779	255	41,576	725	1886	59,857	55,127
ALAI	8597	14,516	250	34,200	629	2052	60,245	55,657
OLAI	5579	17,522	250	33,911	646	2717	60,626	55,843

AE adverse event, ALAI aripiprazole long-acting injectable, HLAI haloperidol long-acting injectable, OLAI olanzapine long-acting injectable, OO oral olanzapine, PLAI paliperidone long-acting injectable, RLAI risperidone long-acting injectable

^aDiscounted at 4 %